<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Obesity in adults: Prevalence, screening, and evaluation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Obesity in adults: Prevalence, screening, and evaluation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Obesity in adults: Prevalence, screening, and evaluation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Leigh Perreault, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">F Xavier Pi-Sunyer, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara Swenson, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The morbidity and mortality associated with being considered overweight or having obesity<sup> </sup>have been known to the medical profession for more than 2000 years [<a href="#rid1">1</a>]. According to the World Health Organization (WHO), obesity is defined as “excess or abnormal fat accumulation that presents a risk to health” [<a href="#rid2">2</a>]. The Centers for Disease Control and Prevention (CDC) defines it as “weight that is considered higher than what is considered healthy for a given height is described as overweight or obesity” [<a href="#rid3">3</a>]. Both use body mass index (BMI) to further define these terms, with a BMI of 25 to 29.9 kg/m<sup>2 </sup>considered overweight and ≥30 kg/m<sup>2 </sup>as obesity. However defined (by WHO, CDC, or other), obesity is a chronic disease that is increasing in prevalence in adults, adolescents, and children and is now considered to be a global epidemic. Screening for obesity can identify high-risk patients who may not otherwise receive counseling about health risks, lifestyle changes, obesity treatment options, and risk factor reduction. Evaluation of a patient who is overweight or with obesity should include both clinical and laboratory studies; the combined information is used to characterize the type and severity of obesity, determine health risk, and provide a basis for selecting therapy.</p><p>The prevalence of obesity, the approach to screening, and the clinical evaluation of obesity in adults will be reviewed here. The health risks associated with obesity and approach to treatment are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences"</a> and  <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">"Obesity in adults: Overview of management"</a>.)</p><p class="headingAnchor" id="H1622499"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>Obesity, a chronic disease that is increasing in prevalence globally, is a major contributor to poor health in most countries [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H2001228799"><span class="h2">United States</span><span class="headingEndMark"> — </span>Estimates of the prevalence of obesity in the United States using consistent, standardized methods have been ongoing since 1960 [<a href="#rid5">5,6</a>]. Prevalence data have been collected in two ways: annual telephone surveys conducted by state Departments of Health in collaboration with the Centers for Disease Control and Prevention (the Behavioral Risk Factor Surveillance System [BRFSS]), and directly measured height and weight obtained in field surveys by the National Center for Health Statistics as the National Health and Nutrition Examination Survey (NHANES).</p><p>Data from BRFSS consistently report obesity prevalence rates lower than those found in the NHANES surveys. This is due to self-report bias (eg, people under-reporting their weight, over-reporting their height, or both) during telephone surveys. Thus, it is essential to identify the data source when evaluating obesity prevalence information.</p><p>Based upon data collected for NHANES from 1988 to 1994, 1999 to 2000, and 2017 to 2018, the age-adjusted overall prevalence of obesity in the United States increased progressively from 22.9 to 30.5 to 42.4 percent  (<a class="graphic graphic_figure graphicRef132302" href="/z/d/graphic/132302.html" rel="external">figure 1</a>) [<a href="#rid7">7</a>]. In 2017 to 2018, the prevalence of obesity was the same in adult males and females [<a href="#rid8">8</a>].</p><p>The age-adjusted prevalence of class III obesity (body mass index [BMI] ≥40 kg/m<sup>2</sup>), sometimes referred to as severe obesity, has risen from 5.7 percent to 9.2 percent between 2007 and 2018 [<a href="#rid7">7,8</a>].</p><p>In 2018, the self-reported prevalence of obesity in United States adults ranged from 23 percent in Colorado to almost 40 percent in Mississippi and West Virginia [<a href="#rid9">9</a>]. The prevalence of self-reported obesity was generally higher in the Midwest and the South than in the Northeast and the West. Although the regional prevalence of self-reported obesity generally parallels the results obtained by more objective surveys, the reported degree of obesity is lower [<a href="#rid10">10-12</a>].</p><p>Projections using extrapolated data from BRFSS and NHANES suggest that by 2030, almost half of all United States adults will be obese, and almost one-fourth will be severely obese [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H1622524"><span class="h2">Canada</span><span class="headingEndMark"> — </span>The prevalence of obesity is rising in Canada. In 1985, fewer than 10 percent of people in nine of the provinces were obese; by 1990, this was true for only three of the provinces. By 1994, five provinces had obesity rates between 15 to 19 percent [<a href="#rid14">14</a>]. By 2016, more than 22 percent of males and 20 percent of females in all of Canada were obese, a steady increase [<a href="#rid15">15,16</a>].</p><p class="headingAnchor" id="H1622530"><span class="h2">Global</span><span class="headingEndMark"> — </span>In 2015, roughly 604 million adults had obesity worldwide [<a href="#rid17">17</a>]. Since 1980, the prevalence of obesity has doubled in more than 70 countries and has continued to increase in most other countries as well. Rates of increase were similar between males and females in all age groups and were highest during early adulthood. Additionally, in 2015, at all socioeconomic levels and for all age groups, the prevalence of obesity was higher for females than males. The prevalence of obesity increased the greatest from 1980 to 2015 for males age 25 to 29 in low- to middle-income countries, from 11.1 to 38.3 percent.</p><p class="headingAnchor" id="H2"><span class="h1">SCREENING</span></p><p class="headingAnchor" id="H1655565409"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>We suggest that all adult patients be screened for overweight and obesity by measuring BMI as part of their routine physical examination. We also recommend measuring waist circumference in those with BMI between 25 and 35 kg/m<sup>2</sup>. This is consistent with guidelines for the screening and evaluation of overweight and obesity [<a href="#rid18">18-25</a>].</p><p class="headingAnchor" id="H1543165865"><span class="h2">Rationale</span><span class="headingEndMark"> — </span>Obesity is associated with a significant increase in morbidity (including diabetes mellitus, hypertension, dyslipidemia, heart disease, stroke, sleep apnea, and cancer) and mortality. Weight loss is associated with a reduction in obesity-associated morbidity. (See  <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences"</a> and  <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">"Obesity in adults: Overview of management", section on 'Importance of weight loss'</a>.)</p><p>Without screening, many high-risk patients may not receive counseling about health risks, lifestyle changes, obesity treatment options, and risk factor reduction.</p><p>Clinicians miss opportunities to screen, diagnose, and manage obesity. As an example, in a study of 20,383 patients with BMI ≥25 kg/m<sup>2</sup> in 57 primary care practices, only 12 percent had a conversation with their primary care provider about their weight that resulted in the use of a weight-related ICD-10 code for billing. Only 6 percent received continuing care for their weight (ie, prescription of anti-obesity medication or referral to a dietician or specialist) [<a href="#rid26">26</a>]. Similarly, a 2018 report of 3008 patients with obesity found that only 55 percent had a diagnosis of obesity and even fewer had an obesity management plan documented by their clinicians [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H4087936049"><span class="h2">Barriers to screening</span><span class="headingEndMark"> — </span>A frequently cited barrier to screening is the potential risk of stigma associated with a diagnosis of obesity. Use of sensitive language around obesity (such as "unhealthy" or "excess" weight) and education about the increasing number of treatment options can improve patient engagement in their care. Using language such as “person with obesity” rather than “obese person" may also help to reduce stigma and improve patient engagement.</p><p class="headingAnchor" id="H4"><span class="h2">Measurements</span><span class="headingEndMark"> — </span>All adult patients should be screened for overweight and obesity by measuring height, weight, and calculating body mass index (BMI) as part of the routine physical examination. In addition, we suggest measuring waist circumference in those with BMI between 25 and 35 kg/m<sup>2</sup>  (<a class="graphic graphic_figure graphicRef77584" href="/z/d/graphic/77584.html" rel="external">figure 2</a>) as abdominal adiposity (and associated risk) may not be captured in this BMI range, particularly for Asian individuals. (See <a class="local">'Waist circumference'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h3">Body mass index</span><span class="headingEndMark"> — </span>Measuring BMI is the generally accepted first step to determine the degree of overweight. The BMI is easy to measure, reliable, and correlated with percentage of body fat and body fat mass [<a href="#rid28">28</a>]. BMI provides a better estimate of total body fat compared with body weight alone [<a href="#rid29">29</a>].</p><p>Clinicians should be aware that BMI may overestimate the degree of adiposity in individuals who are overweight but very muscular (for example, professional athletes or bodybuilders) and underestimate it in older persons due to loss of muscle mass associated with aging. In addition, among older adults in whom there is a loss of height (eg, due to osteoporosis, kyphosis), we use the patient's current, measured height to calculate the BMI [<a href="#rid30">30</a>]. Although failing to consider height loss may suggest an artifactually high calculated BMI, there is typically an associated loss of muscle mass (and weight) with aging such that the calculated BMI reflects the degree of true adiposity.</p><p>Measurement of waist circumference in conjunction with BMI can provide additional information on risk. (See <a class="local">'Waist circumference'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h4">Calculation</span><span class="headingEndMark"> — </span>The BMI is the most practical first step for evaluating the degree of excess weight. It is calculated from the weight and square of the height as follows:</p><div class="formulaContainer"><div class="formula"><p class="bulletIndent1">BMI = Body weight (in kg) ÷ height (in meters) squared</p></div></div><p></p><p>The BMI can also be obtained from a calculator (<a class="calc calc_professional" href="/z/d/html/13478.html" rel="external">calculator 1</a>).</p><p class="headingAnchor" id="H7"><span class="h4">BMI-based classifications</span><span class="headingEndMark"> — </span>Body mass index (BMI) classifications are based upon risk of cardiovascular disease (CVD) [<a href="#rid31">31</a>]. The recommended classifications for BMI adopted by the National Institutes of Health (NIH) and World Health Organization (WHO) [<a href="#rid18">18,32</a>] for White, Hispanic, and Black individuals are  (<a class="graphic graphic_table graphicRef97661" href="/z/d/graphic/97661.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Underweight – &lt;18.5 kg/m<sup>2</sup></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normal weight – ≥18.5 to 24.9 kg/m<sup>2</sup></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overweight – ≥25.0 to 29.9 kg/m<sup>2</sup></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obesity – ≥30 kg/m<sup>2</sup></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Class I – 30.0 to 34.9 kg/m<sup>2</sup></p><p class="bulletIndent2"><span class="glyph">•</span>Class II – 35.0 to 39.9 kg/m<sup>2</sup></p><p class="bulletIndent2"><span class="glyph">•</span>Class III – ≥40 kg/m<sup>2</sup> (also referred to as severe, extreme, or massive obesity)</p><p></p><p>The cutoffs underestimate the risk associated with obesity, such as diabetes, in the Asian population. In some populations, the level of risk in terms of percent body fat is reached at a much lower BMI (South Asian subjects) and in others a higher BMI (Black subjects) compared with White subjects [<a href="#rid33">33-35</a>]. This was illustrated in a study comparing South Asian and White individuals [<a href="#rid34">34</a>]. The mean BMI associated with development of an adverse metabolic profile (defined by markers of glucose and lipid metabolism) was 21 kg/m<sup>2</sup> among South Asian individuals and 30 kg/m<sup>2</sup> among White individuals.</p><p class="headingAnchor" id="H8"><span class="h3">Waist circumference</span><span class="headingEndMark"> — </span>In addition to measuring BMI, we suggest measuring waist circumference in patients considered overweight or who have obesity to assess abdominal obesity. A waist circumference of ≥40 in (102 cm) for males and ≥35 in (88 cm) for females is considered elevated and indicative of increased cardiometabolic risk [<a href="#rid19">19</a>]. Waist circumference measurement is unnecessary in patients with BMI ≥35 kg/m<sup>2</sup> as almost all individuals with this BMI also have an abnormal waist circumference and are already at a high risk from their adiposity.</p><p>Waist circumference is a measurement of abdominal obesity and provides independent risk information that is not accounted for by BMI [<a href="#rid36">36</a>]. Patients with abdominal obesity (also called central adiposity, visceral, android, or male-type obesity) are at increased risk for heart disease, diabetes, hypertension, dyslipidemia, nonalcoholic fatty liver disease [<a href="#rid37">37-41</a>], and have higher overall mortality rates [<a href="#rid36">36,42-44</a>]. Waist circumference is used with BMI for identifying adults at increased risk for morbidity and mortality, particularly in the BMI range 25 to 35 kg/m<sup>2</sup>.</p><p>The waist circumference is measured with a flexible tape placed on a horizontal plane at the level of the iliac crest as seen from the anterior view  (<a class="graphic graphic_figure graphicRef77584" href="/z/d/graphic/77584.html" rel="external">figure 2</a>). There is population variability in waist circumference values that predict increased risk. As an example, Japanese Americans and Indians from South Asia have more total fat and visceral fat and therefore may be at higher risk of developing type 2 diabetes for a given BMI than White individuals [<a href="#rid33">33,45</a>]. A waist circumference ≥31 in (80 cm) in Asian females and ≥35 in (90 cm) in Asian males is considered abnormal. Although dual-energy x-ray absorptiometry (DXA), computed tomography (CT), and magnetic resonance imaging (MRI) provide a more direct measurement than waist circumference for assessing the distribution of body fat, they are costly exams and are generally reserved for use as research tools.</p><p>Measurement of the waist-to-hip ratio provides no advantage over waist circumference alone and is infrequently used by clinicians. It is not recommended as part of the routine obesity evaluation by the American Heart Association (AHA)/American College of Cardiology (ACC)/The Obesity Society (TOS) guideline, although it was in the previous version [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H13187459"><span class="h1">EVALUATION OF PATIENTS WITH OBESITY</span><span class="headingEndMark"> — </span>In patients considered overweight (body mass index [BMI] ≥25 kg/m<sup>2</sup>) or who have abdominal obesity (waist circumference greater than ≥35 in [88 cm] in females or ≥40 in [102 cm] in males), assessment of the etiology of the weight gain and its associated health risk should be undertaken. Specifically, evaluation of patients who are overweight or with obesity includes a history, physical examination, and measurement of fasting glucose (or glycated hemoglobin [A1C]), thyroid-stimulating hormone (TSH), liver enzymes, and fasting lipids  (<a class="graphic graphic_figure graphicRef69717" href="/z/d/graphic/69717.html" rel="external">figure 3</a>). Subsequent intervention, if necessary, is based upon historical, physical, and/or laboratory results in the setting of shared decision making with the patient. (See  <a class="medical medical_review" href="/z/d/html/5377.html" rel="external">"Obesity in adults: Etiologies and risk factors"</a>.)</p><p class="headingAnchor" id="H13187465"><span class="h2">Investigating the cause</span><span class="headingEndMark"> — </span>Many factors contribute to the development of obesity  (<a class="graphic graphic_table graphicRef55594" href="/z/d/graphic/55594.html" rel="external">table 2</a>). However, most cases of obesity are related to behaviors such as a sedentary lifestyle and increased caloric intake. Although secondary causes of obesity are uncommon, they should be considered and ruled out [<a href="#rid41">41</a>].</p><p>To determine etiology and plan future management strategies, additional medical history should include age at onset of weight gain, events associated with weight gain, previous weight loss attempts, change in dietary patterns, history of exercise, current and past medications, and history of smoking cessation. Medications are a common cause of weight gain, in particular insulin, sulfonylureas, thiazolidinediones, glucocorticoids, and antipsychotics  (<a class="graphic graphic_table graphicRef132587" href="/z/d/graphic/132587.html" rel="external">table 3</a>). Smoking cessation is also associated with weight gain. (See  <a class="medical medical_review" href="/z/d/html/16706.html" rel="external">"Benefits and consequences of smoking cessation", section on 'Weight gain'</a>.)</p><p>Females have more body fat as a percent of body weight than males from puberty onward and tend to gain more fat during adult life than males. In addition, females may experience modest but adverse increases in body weight and fat distribution after a first pregnancy that persist. (See  <a class="medical medical_review" href="/z/d/html/127985.html" rel="external">"Overview of the postpartum period: Disorders and complications", section on 'Postpartum weight retention'</a>.)</p><p>Findings from physical examination that might point to a secondary or related cause of obesity include goiter (hypothyroidism); proximal muscle weakness, moon facies, and/or purple striae (Cushing's syndrome); and acne and/or hirsutism (polycystic ovary syndrome [PCOS]). (See  <a class="medical medical_review" href="/z/d/html/5377.html" rel="external">"Obesity in adults: Etiologies and risk factors"</a>.)</p><p>Additional testing may be required depending upon the findings on history, physical examination, and initial blood tests. This could include laboratory tests to assess the hypothalamic-pituitary axis if there are signs of disorders such as Cushing's syndrome, growth hormone deficiency, or hypothalamic obesity. (See  <a class="medical medical_review" href="/z/d/html/5377.html" rel="external">"Obesity in adults: Etiologies and risk factors", section on 'Conditions associated with weight gain'</a>.)</p><p>Routine genetic testing is not recommended, as monogenic disorders that include obesity are rare and usually present in childhood. Measurement of metabolic rate is not recommended, as it is not widely available and may be misinterpreted. (See  <a class="medical medical_review" href="/z/d/html/5378.html" rel="external">"Obesity: Genetic contribution and pathophysiology", section on 'Heritable factors'</a>.)</p><p class="headingAnchor" id="H13187471"><span class="h2">Assessing obesity-related health risk</span><span class="headingEndMark"> — </span>Assessment of an individual's overall risk status includes determining the degree of overweight (BMI) and the presence of abdominal obesity (waist circumference), cardiovascular risk factors, sleep apnea, nonalcoholic fatty liver disease, symptomatic osteoarthritis, and other obesity-related comorbidities. The coexistence of several diseases, including established coronary heart disease (CHD), other atherosclerotic disease, type 2 diabetes mellitus, and sleep apnea, places patients in a very high-risk category for subsequent mortality. (See  <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences", section on 'Mortality'</a>.)</p><p>Assessment and management of these diseases is an important part of the evaluation and management of the adult who is considered overweight or who has obesity. Further, the relationship between BMI and risk allows identification of BMI categories that can be used to guide selection of weight loss therapy [<a href="#rid19">19,20</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weight history </strong>–<strong> </strong>The age of onset of obesity is of some importance in determining health risk. Children with a low birth weight and those whose weight rises more rapidly in the first 10 years are at high risk for diabetes as adults [<a href="#rid46">46</a>]. The risk for any given degree of obesity seems to be greater in patients whose obesity begins before the age of 40 years, probably because of the longer time period over which comorbid conditions, such as diabetes mellitus and hypertension, can develop [<a href="#rid47">47</a>]. Children with obesity at age 7 years and continue with obesity throughout puberty will almost certainly have it as adults [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/z/d/html/5874.html" rel="external">"Definition, epidemiology, and etiology of obesity in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1">Weight gain after age 18 years is also important. Even very modest weight gain (≥5 kg) after age 18 years in females and after age 20 years in males increases the risk of CHD and type 2 diabetes at all levels of initial BMI [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular risk factors </strong>–<strong> </strong>Cardiovascular risk factors should be identified, including hypertension, dyslipidemia (reduced levels of high-density lipoprotein [HDL] or elevated levels of low-density lipoprotein [LDL]), elevated triglycerides, impaired fasting glucose or diabetes, obstructive sleep apnea, and cigarette smoking  (<a class="graphic graphic_figure graphicRef69717" href="/z/d/graphic/69717.html" rel="external">figure 3</a>) [<a href="#rid32">32</a>]. These risk factors should be managed to mitigate cardiovascular disease (CVD) risk independently of weight loss efforts. (See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> <strong>comorbidities </strong>–<strong> </strong>Obesity is also associated with other disorders that do not increase cardiovascular risk but are associated with significant morbidity. Examples include symptomatic osteoarthritis, cholelithiasis, nonalcoholic fatty liver disease, PCOS, depression, and impaired quality of life. Attenuation of these comorbidities may be achieved through weight loss. (See  <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences"</a>.)</p><p></p><p class="headingAnchor" id="H10745272"><span class="h2">Candidates for weight-loss interventions</span><span class="headingEndMark"> — </span>Because of known health risks associated with excess body weight [<a href="#rid31">31</a>], people with BMI &gt;25 kg/m<sup>2</sup> are candidates for weight-loss interventions. Nevertheless, there are few data to support specific targets, and the approach described below is based upon expert consensus. The goal of therapy is to prevent, treat, or reverse the complications of obesity, including decrements in quality of life. (See  <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">"Obesity in adults: Overview of management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with BMI between 24.9 and 30 kg/m<sup>2</sup> who do not have risk factors for CVD or other obesity-related comorbidities, counseling regarding prevention of further weight gain is important. This includes advice on dietary habits and physical activity. (See  <a class="medical medical_review" href="/z/d/html/5379.html" rel="external">"Obesity in adults: Role of physical activity and exercise", section on 'Exercise to prevent weight gain'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with BMI ≥30 kg/m<sup>2</sup> or between 24.9 and 30 kg/m<sup>2</sup> and with one or more risk factors for CVD (diabetes, hypertension, dyslipidemia), or with obstructive sleep apnea or symptomatic osteoarthritis, should be counseled about weight-loss interventions (diet, physical activity, behavioral modification) [<a href="#rid19">19</a>].</p><p></p><p>Specific recommendations for the treatment of obesity are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">"Obesity in adults: Overview of management"</a> and  <a class="medical medical_review" href="/z/d/html/5375.html" rel="external">"Obesity in adults: Dietary therapy"</a> and  <a class="medical medical_review" href="/z/d/html/5376.html" rel="external">"Obesity in adults: Drug therapy"</a> and  <a class="medical medical_review" href="/z/d/html/5382.html" rel="external">"Obesity in adults: Behavioral therapy"</a>.)</p><p class="headingAnchor" id="H1387299383"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111344.html" rel="external">"Society guideline links: Obesity in adults"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15486.html" rel="external">"Patient education: Weight loss treatments (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/1988.html" rel="external">"Patient education: Losing weight (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/1987.html" rel="external">"Patient education: Weight loss surgery and procedures (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest that all adult patients be screened for overweight and obesity (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). This is done by measuring body mass index (BMI) (<a class="calc calc_professional" href="/z/d/html/13478.html" rel="external">calculator 1</a>) at the routine physical examination. In addition, we suggest measuring waist circumference in those with BMI between 25 and 35 kg/m<sup>2 </sup>(<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>)<sup> </sup> (<a class="graphic graphic_figure graphicRef77584" href="/z/d/graphic/77584.html" rel="external">figure 2</a>) as abdominal adiposity (and associated risk) may not be captured in this BMI range. Waist circumference measurement is unnecessary in patients with BMI ≥35 kg/m<sup>2</sup>. (See <a class="local">'Measurements'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>BMI classifications are based upon risk of cardiometabolic disease  (<a class="graphic graphic_table graphicRef97661" href="/z/d/graphic/97661.html" rel="external">table 1</a>). The classification is used for identifying adults at increased risk for morbidity and mortality due to obesity. However, the relationship between percent body fat and BMI is different among different patient populations. In White, Hispanic, and Black individuals, overweight is defined as a BMI of 25 to 29.9 kg/m<sup>2</sup> and obesity as a BMI of ≥30 kg/m<sup>2</sup>. The cutoffs underestimate the risk associated with obesity in the Asian population. (See <a class="local">'BMI-based classifications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Waist circumference is a measurement of abdominal obesity and provides independent risk information that is not accounted for by BMI. Patients with abdominal obesity (also called central adiposity, visceral, android, or male-type obesity) have an increased risk for overall mortality, heart disease, diabetes, hypertension, dyslipidemia, and nonalcoholic fatty liver disease. A waist circumference of ≥40 in (102 cm) for males and ≥35 in (88 cm) for females is considered elevated and indicative of increased cardiometabolic risk. A waist circumference ≥31 in (80 cm) in Asian females and ≥35 in (90 cm) in Asian males is considered abnormal. (See <a class="local">'Waist circumference'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In individuals with BMI ≥25 kg/m<sup>2</sup> or a waist circumference ≥35 in (88 cm) (females) or ≥40 in (102 cm) (males), we suggest further evaluation to assess overall risk status  (<a class="graphic graphic_figure graphicRef69717" href="/z/d/graphic/69717.html" rel="external">figure 3</a>) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>).</p><p></p><p class="bulletIndent1">Assessment of an individual's overall risk status includes determining the degree of overweight (BMI) and the presence of abdominal obesity (waist circumference), cardiometabolic risk factors, obstructive sleep apnea, symptomatic osteoarthritis, and other comorbidities. The evaluation includes a history, physical examination, and measurement of fasting glucose (or glycated hemoglobin [A1C]), thyroid-stimulating hormone (TSH), liver enzymes, and fasting lipids  (<a class="graphic graphic_figure graphicRef69717" href="/z/d/graphic/69717.html" rel="external">figure 3</a>). Subsequent intervention, if necessary, is based upon overall risk assessment. The coexistence of several diseases, including established coronary heart disease (CHD), other atherosclerotic disease, type 2 diabetes mellitus, and sleep apnea places patients in a very high-risk category for subsequent mortality. (See <a class="local">'Evaluation of patients with obesity'</a> above.)</p><p></p><p class="bulletIndent1">Many factors contribute to the development of obesity  (<a class="graphic graphic_table graphicRef55594" href="/z/d/graphic/55594.html" rel="external">table 2</a>). However, most cases of obesity are related to behaviors such as a sedentary lifestyle and increased caloric intake. Although secondary causes of obesity are uncommon, they should be considered and ruled out, typically with history and physical examination. (See <a class="local">'Investigating the cause'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All individuals who would benefit from weight loss should receive counseling on diet, physical activity, behavioral modification, and goals for weight loss. Individuals who do not need to lose weight can be counseled regarding prevention of weight gain. The relationship between BMI and risk allows identification of several levels that can be used to guide further selection of therapy. (See <a class="local">'Candidates for weight-loss interventions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Specific recommendations for the treatment of obesity are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">"Obesity in adults: Overview of management"</a> and  <a class="medical medical_review" href="/z/d/html/5375.html" rel="external">"Obesity in adults: Dietary therapy"</a> and  <a class="medical medical_review" href="/z/d/html/5376.html" rel="external">"Obesity in adults: Drug therapy"</a> and  <a class="medical medical_review" href="/z/d/html/5382.html" rel="external">"Obesity in adults: Behavioral therapy"</a>.)</p><p></p><p class="headingAnchor" id="H3017787380"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges George Bray, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Bray GA. The Battle of the Bulge: A History of Obesity Research, Dorrance, 2007.</li><li class="breakAll">World Health Organization. Obesity. Available at: https://www.who.int/health-topics/obesity#tab=tab_1 (Accessed on October 21, 2022).</li><li class="breakAll">Centers for Disease Control and Prevention. Defining adult overweight &amp; obesity. Available at: https://www.cdc.gov/obesity/basics/adult-defining.html (Accessed on October 21, 2022).</li><li><a class="nounderline abstract_t">NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet 2016; 387:1377.</a></li><li><a class="nounderline abstract_t">Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288:1723.</a></li><li><a class="nounderline abstract_t">Ljungvall A, Zimmerman FJ. Bigger bodies: long-term trends and disparities in obesity and body-mass index among U.S. adults, 1960-2008. Soc Sci Med 2012; 75:109.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Overweight and obesity: Adult obesity facts. Available at: https://www.cdc.gov/obesity/data/adult.html (Accessed on March 07, 2021).</li><li><a class="nounderline abstract_t">Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018. NCHS Data Brief 2020; :1.</a></li><li class="breakAll">https://www.cdc.gov/obesity/data/prevalence-maps.html (Accessed on December 20, 2019).</li><li><a class="nounderline abstract_t">Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307:491.</a></li><li><a class="nounderline abstract_t">Ezzati M, Martin H, Skjold S, et al. Trends in national and state-level obesity in the USA after correction for self-report bias: analysis of health surveys. J R Soc Med 2006; 99:250.</a></li><li><a class="nounderline abstract_t">Ward ZJ, Long MW, Resch SC, et al. Redrawing the US Obesity Landscape: Bias-Corrected Estimates of State-Specific Adult Obesity Prevalence. PLoS One 2016; 11:e0150735.</a></li><li><a class="nounderline abstract_t">Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med 2019; 381:2440.</a></li><li><a class="nounderline abstract_t">Katzmarzyk PT. The Canadian obesity epidemic, 1985-1998. CMAJ 2002; 166:1039.</a></li><li><a class="nounderline abstract_t">Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384:766.</a></li><li class="breakAll">http://obesitycanada.ca/wp-content/uploads/2020/08/2-Epidemiology-of-Adult-Obesity-4-FINAL.pdf (Accessed on April 06, 2021).</li><li><a class="nounderline abstract_t">GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med 2017; 377:13.</a></li><li><a class="nounderline abstract_t">Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894:i.</a></li><li><a class="nounderline abstract_t">Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014; 129:S102.</a></li><li class="breakAll">The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf (Accessed on January 23, 2013).</li><li><a class="nounderline abstract_t">Moyer VA, U.S. Preventive Services Task Force. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:373.</a></li><li><a class="nounderline abstract_t">ACOG Committee on Gynecologic Practice. ACOG committee opinion. Number 319, October 2005. The role of obstetrician-gynecologist in the assessment and management of obesity. Obstet Gynecol 2005; 106:895.</a></li><li><a class="nounderline abstract_t">Tsai AG, Bessesen DH. Obesity. Ann Intern Med 2019; 170:ITC33.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Curry SJ, Krist AH, et al. Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: US Preventive Services Task Force Recommendation Statement. JAMA 2018; 320:1163.</a></li><li><a class="nounderline abstract_t">Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ 2020; 192:E875.</a></li><li><a class="nounderline abstract_t">Perreault L, Suresh K, Rodriguez C, et al. Baseline Characteristics of PATHWEIGH: A Stepped-Wedge Cluster Randomized Study for Weight Management in Primary Care. Ann Fam Med 2023; 21:249.</a></li><li><a class="nounderline abstract_t">Kaplan LM, Golden A, Jinnett K, et al. Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study. Obesity (Silver Spring) 2018; 26:61.</a></li><li><a class="nounderline abstract_t">Gallagher D, Visser M, Sepúlveda D, et al. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol 1996; 143:228.</a></li><li><a class="nounderline abstract_t">Mei Z, Grummer-Strawn LM, Pietrobelli A, et al. Validity of body mass index compared with other body-composition screening indexes for the assessment of body fatness in children and adolescents. Am J Clin Nutr 2002; 75:978.</a></li><li><a class="nounderline abstract_t">Onwudiwe NC, Stuart B, Zuckerman IH, Sorkin JD. Obesity and medicare expenditure: accounting for age-related height loss. Obesity (Silver Spring) 2011; 19:204.</a></li><li><a class="nounderline abstract_t">Prospective Studies Collaboration, Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373:1083.</a></li><li><a class="nounderline abstract_t">Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res 1998; 6 Suppl 2:51S.</a></li><li><a class="nounderline abstract_t">Deurenberg P, Yap M, van Staveren WA. Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes Relat Metab Disord 1998; 22:1164.</a></li><li><a class="nounderline abstract_t">Razak F, Anand SS, Shannon H, et al. Defining obesity cut points in a multiethnic population. Circulation 2007; 115:2111.</a></li><li><a class="nounderline abstract_t">Hsu WC, Araneta MR, Kanaya AM, et al. BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. Diabetes Care 2015; 38:150.</a></li><li><a class="nounderline abstract_t">Gnatiuc L, Alegre-Díaz J, Wade R, et al. General and Abdominal Adiposity and Mortality in Mexico City: A Prospective Study of 150 000 Adults. Ann Intern Med 2019; 171:397.</a></li><li><a class="nounderline abstract_t">Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 2004; 79:379.</a></li><li><a class="nounderline abstract_t">Simpson JA, MacInnis RJ, Peeters A, et al. A comparison of adiposity measures as predictors of all-cause mortality: the Melbourne Collaborative Cohort Study. Obesity (Silver Spring) 2007; 15:994.</a></li><li><a class="nounderline abstract_t">Koster A, Leitzmann MF, Schatzkin A, et al. Waist circumference and mortality. Am J Epidemiol 2008; 167:1465.</a></li><li><a class="nounderline abstract_t">Jacobs EJ, Newton CC, Wang Y, et al. Waist circumference and all-cause mortality in a large US cohort. Arch Intern Med 2010; 170:1293.</a></li><li><a class="nounderline abstract_t">Tsai AG, Wadden TA. In the clinic: obesity. Ann Intern Med 2013; 159:ITC3.</a></li><li><a class="nounderline abstract_t">Jayedi A, Soltani S, Zargar MS, et al. Central fatness and risk of all cause mortality: systematic review and dose-response meta-analysis of 72 prospective cohort studies. BMJ 2020; 370:m3324.</a></li><li><a class="nounderline abstract_t">Liu J, Jin X, Feng Z, Huang J. The association of central and extremity circumference with all-cause mortality and cardiovascular mortality: a cohort study. Front Cardiovasc Med 2023; 10:1251619.</a></li><li><a class="nounderline abstract_t">Khan I, Chong M, Le A, et al. Surrogate Adiposity Markers and Mortality. JAMA Netw Open 2023; 6:e2334836.</a></li><li><a class="nounderline abstract_t">Gallagher D, Heymsfield SB, Heo M, et al. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr 2000; 72:694.</a></li><li><a class="nounderline abstract_t">Bhargava SK, Sachdev HS, Fall CH, et al. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med 2004; 350:865.</a></li><li><a class="nounderline abstract_t">Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341:427.</a></li><li><a class="nounderline abstract_t">Ogden CL, Carroll MD, Lawman HG, et al. Trends in Obesity Prevalence Among Children and Adolescents in the United States, 1988-1994 Through 2013-2014. JAMA 2016; 315:2292.</a></li></ol></div><div id="topicVersionRevision">Topic 5372 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Bray GA. The Battle of the Bulge: A History of Obesity Research, Dorrance, 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.who.int/health-topics/obesity#tab=tab_1" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : World Health Organization. Obesity. Available at: https://www.who.int/health-topics/obesity#tab=tab_1 (Accessed on October 21, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cdc.gov/obesity/basics/adult-defining.html" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Centers for Disease Control and Prevention. Defining adult overweight &amp; obesity. Available at: https://www.cdc.gov/obesity/basics/adult-defining.html (Accessed on October 21, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27115820" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12365955" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence and trends in obesity among US adults, 1999-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22551821" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Bigger bodies: long-term trends and disparities in obesity and body-mass index among U.S. adults, 1960-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22551821" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Bigger bodies: long-term trends and disparities in obesity and body-mass index among U.S. adults, 1960-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32487284" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32487284" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22253363" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16672759" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Trends in national and state-level obesity in the USA after correction for self-report bias: analysis of health surveys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26954566" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Redrawing the US Obesity Landscape: Bias-Corrected Estimates of State-Specific Adult Obesity Prevalence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31851800" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12002980" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The Canadian obesity epidemic, 1985-1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24880830" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24880830" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28604169" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Health Effects of Overweight and Obesity in 195 Countries over 25 Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11234459" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Obesity: preventing and managing the global epidemic. Report of a WHO consultation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24222017" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24222017" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22733087" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16199657" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : ACOG committee opinion. Number 319, October 2005. The role of obstetrician-gynecologist in the assessment and management of obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30831593" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30326502" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32753461" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Obesity in adults: a clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37217322" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Baseline Characteristics of PATHWEIGH: A Stepped-Wedge Cluster Randomized Study for Weight Management in Primary Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29086529" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8561156" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12036802" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Validity of body mass index compared with other body-composition screening indexes for the assessment of body fatness in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20651701" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Obesity and medicare expenditure: accounting for age-related height loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19299006" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9813653" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9877251" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Body mass index and percent body fat: a meta analysis among different ethnic groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17420343" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Defining obesity cut points in a multiethnic population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25538311" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31404923" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : General and Abdominal Adiposity and Mortality in Mexico City: A Prospective Study of 150 000 Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14985210" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Waist circumference and not body mass index explains obesity-related health risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17426335" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A comparison of adiposity measures as predictors of all-cause mortality: the Melbourne Collaborative Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18417494" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Waist circumference and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20696950" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Waist circumference and all-cause mortality in a large US cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24026335" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : In the clinic: obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32967840" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Central fatness and risk of all cause mortality: systematic review and dose-response meta-analysis of 72 prospective cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37719982" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The association of central and extremity circumference with all-cause mortality and cardiovascular mortality: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37728925" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Surrogate Adiposity Markers and Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10966886" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14985484" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10432328" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Guidelines for healthy weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27272581" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Trends in Obesity Prevalence Among Children and Adolescents in the United States, 1988-1994 Through 2013-2014.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
